Bivalve Ether Phospholipid Extraction via Solvent Partitioning

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing plasmalogens-type glycerophospholipids, particularly from chicken tissues, are not sufficient in terms of effectiveness for treating and improving brain diseases, metabolic diseases, infectious diseases, and immune disorders, and lack efficiency in large-scale production.

Innovation Solution

A method involving the processing of bivalve tissues with a water-soluble ketone solvent, followed by extraction with a hydrophobic organic solvent and reaction with phospholipase A1 to obtain purified ether phospholipids, which are then separated using solvent partitioning.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If plasmalogens-type glycerophospholipids are produced from chicken tissues using conventional methods, then production can be achieved on a large scale, but the effectiveness for treating brain diseases and other disorders is insufficient

Engineering Contradiction:
Improveeffectiveness for treating brain diseasesVSAvoidproduction efficiency
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The invention changes the source material parameter from chicken tissues to bivalve tissues, which fundamentally alters the composition and effectiveness of the produced plasmalogens. This parameter change enables both high effectiveness for treating brain diseases and efficient large-scale production, resolving the contradiction between therapeutic reliability and manufacturing ease

Inventive Principle:
Principle #35Parameter changes

2Manufacturing precision

If ether phospholipids are extracted from bivalve tissues using multiple extraction steps, then purity and effectiveness are improved, but production complexity increases

Engineering Contradiction:
Improvepurity of ether phospholipidsVSAvoidproduction process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The invention employs a systematic extraction process that selectively removes ether phospholipids from bivalve tissues through sequential steps: water-soluble ketone solvent extraction to remove neutral fats, followed by hydrophobic organic solvent extraction to isolate glycerophospholipids. This targeted extraction approach achieves high purity while maintaining manageable process complexity

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The production process is divided into distinct sequential stages: (A) neutral fat removal using water-soluble ketone solvent, (B) glycerophospholipid extraction using hydrophobic organic solvent, and (C) enzymatic decomposition with phospholipase A1 followed by solvent partitioning. This segmentation allows each step to be optimized independently, achieving high purity without excessive overall complexity

Inventive Principle:
Principle #1Segmentation

3Ease of manufacture

If conventional extraction methods are used for plasmalogens from chicken breast, then production is easier compared to chicken skin, but the therapeutic effects for brain diseases and metabolic diseases remain insufficient

Engineering Contradiction:
Improveease of productionVSAvoidtherapeutic effectiveness
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The invention changes the fundamental parameter of source tissue from chicken breast to bivalve tissues. This parameter change provides both the ease of large-scale production characteristic of chicken breast and the superior therapeutic effectiveness associated with plasmalogens from bivalve sources, simultaneously resolving both concerns

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The resulting ether phospholipids from bivalve tissues exhibit superior effects in treating and improving brain diseases, metabolic diseases, infectious diseases, and immune disorders, and can be produced on a massive scale with ease.

Implementation Method 1

a step of processing total lipids of bivalve tissues with a water-soluble ketone solvent to get bivalve phospholipids without neutral fat

Methodology Applied
Scientific EffectSolvent extraction: Liquid-Liquid Extraction

Implementation Method 2

a step of providing extraction processing from the bivalve phospholipids without neutral fat obtained by the step (A) with a hydrophobic organic solvent to get glycerophospholipids

Methodology Applied
Scientific EffectSolvent extraction: Liquid-Liquid Extraction

Implementation Method 3

a step of reacting the glycerophospholipids obtained by the step (B) with phospholipase A1 to decompose mixed diacyl-glycerophospholipids

Methodology Applied
Scientific EffectEnzymatic hydrolysis: Hydrolysis

Data Source

PatentEP3241884B1Method for producing ether phospholipid
Publication Date: 2019.12.18 FUJINO TAKEHIKO
  • EP3241884B1 patent drawingFigure 1(a)~2(b)
  • EP3241884B1 patent drawingFigure 3(a)~3(c)

AI summary

[PROBLEM TO BE SOLVED] It enables any superior ether phospholipids to the conventional ones and a method for producing the same in an easy manner on a massive scale, in light of effects of treating and improving brain diseases such as Alzheimer's disease, Parkinson disease, depression and schizophrenia, metabolic diseases such as diabetes, various infectious diseases, and immune disorders. [SOLUTION] Ether phospholipids are obtained from bivalve tissues such as clams and corbicula by extraction processing. The ether phospholipids exhibit significantly superior effects of the above as compared to the conventional ether phospholipids derived from chicken tissues.